memantine

Summary

Summary: AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.

Top Publications

  1. Ponce Lopez T, Liy Salmeron G, Hong E, Meneses A. Lithium, phenserine, memantine and pioglitazone reverse memory deficit and restore phospho-GSK3? decreased in hippocampus in intracerebroventricular streptozotocin induced memory deficit model. Brain Res. 2011;1426:73-85 pubmed publisher
    ..administration of a glycogen synthase kinase (GSK3) inhibitor, lithium; antidementia drugs: phenserine and memantine, and insulin sensitizer, pioglitazone on memory function of ICV STZ-rats was assessed...
  2. Otton H, Lawson McLean A, Pannozzo M, Davies C, Wyllie D. Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs. Neuropharmacology. 2011;60:388-96 pubmed publisher
    Clinically, amantadine and memantine are drugs whose therapeutic utility is linked to their ability to block N-methyl-D-aspartate receptors (NMDARs) in a voltage-dependent manner...
  3. Brown P, Pugh S, Laack N, Wefel J, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15:1429-37 pubmed publisher
    To determine the protective effects of memantine on cognitive function in patients receiving whole-brain radiotherapy (WBRT).
  4. Esfahani M, Harandi Z, Movasat M, Nikdel M, Adelpour M, Momeni A, et al. Memantine for axonal loss of optic neuritis. Graefes Arch Clin Exp Ophthalmol. 2012;250:863-9 pubmed publisher
    To determine the effect of memantine on axonal loss and visual function during the course of optic neuritis (ON). Sixty ON patients in a single-center, institutional setting were randomly assigned to the memantine or placebo groups...
  5. Wilkinson D, Fox N, Barkhof F, Phul R, Lemming O, Scheltens P. Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. J Alzheimers Dis. 2012;29:459-69 pubmed publisher
    ..BBSI), in patients with probable Alzheimer's disease (AD) over the course of 52 weeks of treatment with memantine or placebo. This was a multi-national, randomized, double-blind, placebo-controlled, fixed-dose 1-year study...
  6. Schneider L, Dagerman K, Higgins J, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68:991-8 pubmed publisher
    We directly assessed the clinical trials' evidence for memantine's efficacy in mild Alzheimer disease (AD)...
  7. Réus G, Abelaira H, Stringari R, Fries G, Kapczinski F, Quevedo J. Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Metab Brain Dis. 2012;27:175-82 pubmed publisher
    b>Memantine is a N-methyl-D-aspartate (NMDA) receptor antagonist and several studies have pointed to the NMDA receptor antagonists as a potential therapeutic target for the treatment of depression...
  8. Neumeister K, Riepe M. Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2012;30:245-51 pubmed publisher
    ..It was our goal to investigate the effects of treatment with donepezil, memantine, and a combination thereof on spatial memory...
  9. Fox C, Crugel M, Maidment I, Auestad B, Coulton S, Treloar A, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS ONE. 2012;7:e35185 pubmed publisher
    ..There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation...

More Information

Publications62

  1. Gauthier S, Molinuevo J. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement. 2013;9:326-31 pubmed publisher
    ..is based on a search of the PubMed database to identify relevant articles concerning combination treatment with memantine and cholinesterase inhibitors (ChEIs)...
  2. Tai K, Truong D. Memantine exacerbates myoclonic jerks in a rat model of posthypoxic myoclonus. Brain Res. 2010;1343:194-8 pubmed publisher
    ..To test this hypothesis, the effect of memantine, an NMDA receptor antagonist, on the intensity of myoclonic jerks and the extent of cerebral ischemia-induced ..
  3. Starck M, Albrecht H, Pöllmann W, Dieterich M, Straube A. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol. 2010;257:322-7 pubmed publisher
    A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple ..
  4. Sozio P, Cerasa L, Laserra S, Cacciatore I, Cornacchia C, Di Filippo E, et al. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease. Eur J Pharm Sci. 2013;49:187-98 pubmed publisher
    ..work, GSH (1) or (R)-?-lipoic acid (LA) (2) have been covalently linked with the NMDA receptor antagonists memantine (MEM)...
  5. Yigit U, Erdenöz S, Uslu U, Oba E, Cumbul A, Cağatay H, et al. An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury. Mol Vis. 2011;17:1024-33 pubmed
    ..treatment methods to rat retinas subjected to acute ischemia reperfusion injury and compares the efficacy of memantine, hyperbaric oxygen (HBO) therapy, and brimonidine by histopathological examination...
  6. Schulz J, Rainer M, Klünemann H, Kurz A, Wolf S, Sternberg K, et al. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. J Alzheimers Dis. 2011;25:463-75 pubmed publisher
    The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer's disease (AD)...
  7. Di Santo S, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. J Alzheimers Dis. 2013;35:349-61 pubmed publisher
    Randomized clinical trials have evaluated the efficacy of acetylcholinesterase inhibitors (AChE-Is) and memantine across a wide range of Alzheimer's disease (AD) severity...
  8. Repantis D, Laisney O, Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010;61:473-81 pubmed publisher
    ..g. acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. Based on a systematic review we found that expectations about the potential of these drugs exceed their actual ..
  9. Martinez Coria H, Green K, Billings L, Kitazawa M, Albrecht M, Rammes G, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol. 2010;176:870-80 pubmed publisher
    b>Memantine is an N-methyl-d-aspartate receptor antagonist that is approved for the treatment of moderate to severe Alzheimer's disease (AD)...
  10. Rive B, Gauthier S, Costello S, Marre C, Francois C. Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease. CNS Drugs. 2013;27:573-82 pubmed publisher
    The N-methyl-D-aspartate receptor antagonist, memantine, is licensed for the treatment of moderate to severe Alzheimer's disease (AD)...
  11. Figueiredo C, Clarke J, Ledo J, Ribeiro F, Costa C, Melo H, et al. Memantine rescues transient cognitive impairment caused by high-molecular-weight a? oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci. 2013;33:9626-34 pubmed publisher
    ..On the other hand, HMW oligomers, but not LMW oligomers, induced oxidative stress in hippocampal neurons. Memantine rescued both neuronal oxidative stress and the transient memory impairment caused by HMW oligomers, but did not ..
  12. Schneider L, Insel P, Weiner M. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol. 2011;68:58-66 pubmed publisher
    ..cognitive impairment (MCI) and mild Alzheimer disease (AD) treated with cholinesterase inhibitors (ChEIs) and memantine hydrochloride. Cohort study. The 59 recruiting sites for the Alzheimer's Disease Neuroimaging Initiative (ADNI)...
  13. Gao Y, Payne R, Schurr A, Hougland T, Lord J, Herman L, et al. Memantine reduces mania-like symptoms in animal models. Psychiatry Res. 2011;188:366-71 pubmed publisher
    b>Memantine, a selective antagonist of the N-methyl-D-aspartate receptor, is approved for the treatment of moderate to severe Alzheimer's disease...
  14. Scott McKean J, Costa A. Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn Mem. 2011;18:774-8 pubmed publisher
    ..In addition, this abnormal level of LTD can be pharmacologically rescued by the NMDA receptor antagonist memantine.
  15. Hemmati F, Dargahi L, Nasoohi S, Omidbakhsh R, Mohamed Z, Chik Z, et al. Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine. Behav Brain Res. 2013;252:415-21 pubmed publisher
    ..Here FTY720 was examined on AD rats in comparison to the only clinically approved NMDA receptor antagonist, Memantine. Passive avoidance task showed significant memory restoration in AD animals received FTY720 comparable to ..
  16. Larsson V, Aarsland D, Ballard C, Minthon L, Londos E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry. 2010;25:1030-8 pubmed publisher
    ..is an analysis of a secondary outcome measure of a larger study already reported, aimed to determine whether memantine has an effect on the sleep disturbances in DLB and PDD patients...
  17. Bassil N, Thaipisuttikul P, Grossberg G. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2010;11:1765-71 pubmed publisher
    ..b>Memantine 10 mg twice daily is the FDA-approved regimen for the treatment of moderate to severe Alzheimer's disease...
  18. Thurtell M, Joshi A, Leone A, Tomsak R, Kosmorsky G, Stahl J, et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol. 2010;67:676-80 pubmed publisher
    We conducted a masked, crossover, therapeutic trial of gabapentin (1,200mg/day) versus memantine (40 mg/day) for acquired nystagmus in 10 patients (aged 28-61 years; 7 female; 3 multiple sclerosis [MS]; 6 post-stroke; 1 post-traumatic)...
  19. Kim Y, Shin J, An Y. Changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy: a preliminary study. Ann Nucl Med. 2010;24:363-9 pubmed publisher
    ..investigate the changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy...
  20. Namba T, Yabe T, Gonda Y, Ichikawa N, Sanagi T, Arikawa Hirasawa E, et al. Pigment epithelium-derived factor up-regulation induced by memantine, an N-methyl-D-aspartate receptor antagonist, is involved in increased proliferation of hippocampal progenitor cells. Neuroscience. 2010;167:372-83 pubmed publisher
    b>Memantine is classified as an NMDA receptor antagonist. We recently reported that memantine promoted the proliferation of neural progenitor cells and the production of mature granule neurons in the adult hippocampus...
  21. Lovera J, Frohman E, Brown T, Bandari D, Nguyen L, Yadav V, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16:715-23 pubmed publisher
    b>Memantine, an NMDA antagonist, is effective for moderate to severe Alzheimer's disease. Determine whether memantine improves cognitive performance (CP) among subjects with multiple sclerosis (MS) and cognitive impairment (CI)...
  22. Clerici F, Vanacore N, Elia A, Spila Alegiani S, Pomati S, Da Cas R, et al. Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. Neurol Sci. 2012;33:23-31 pubmed publisher
    The aim of this study is to evaluate memantine effectiveness on behavioural and psychological symptoms of dementia (BPSD) in clinical practice and to identify variables that may predict the therapy effects...
  23. de Lucena D, Fernandes B, Berk M, Dodd S, Medeiros D, Pedrini M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry. 2009;70:1416-23 pubmed publisher
    ..b>Memantine, a drug approved by the FDA for the treatment of moderate to severe Alzheimer's disease, acts as a weak ..
  24. Ashford J, Adamson M, Beale T, La D, Hernandez B, Noda A, et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia. J Alzheimers Dis. 2011;26 Suppl 3:331-6 pubmed publisher
    ..b>Memantine is thought to benefit the AD brain by stabilizing the NMDA receptors on neurons in turn reducing excitotoxicity...
  25. Wild A, Akyol E, Brothwell S, Kimkool P, Skepper J, Gibb A, et al. Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones. Neuropharmacology. 2013;73:138-46 pubmed publisher
    ..The open channel NMDAR blocker, memantine is used to treat certain neurodegenerative diseases, including Parkinson's disease (PD) and is well tolerated ..
  26. Annweiler C, Herrmann F, Fantino B, Brugg B, Beauchet O. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn Behav Neurol. 2012;25:121-7 pubmed publisher
    To determine whether treatment with memantine plus vitamin D is more effective than memantine or vitamin D alone in improving cognition among patients with Alzheimer disease (AD). We studied 43 white outpatients (mean 84.7 ± 6...
  27. Jamadar S, Devito E, Jiantonio R, Meda S, Stevens M, Potenza M, et al. Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism. Psychopharmacology (Berl). 2012;222:129-40 pubmed publisher
    ..We investigated whether memantine, an NMDA receptor antagonist, differentially influences impulsivity measures and Go/No-Go behavior and fMRI ..
  28. Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, et al. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement. 2009;5:369-74 pubmed publisher
    ..The objective of this post hoc analysis was to assess the treatment effects of Memantine on language in patients with moderate to severe AD, using the recently developed Severe Impairment Battery-..
  29. Stewart S, Jenike E, Hezel D, Stack D, Dodman N, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30:34-9 pubmed publisher
    ..McLean/Massachusetts General Hospital Intensive Residential Treatment (IRT) program, 22 of whom also received memantine augmentation...
  30. McInnes F, Anthony N, Kennedy A, Wheate N. Solid state stabilisation of the orally delivered drugs atenolol, glibenclamide, memantine and paracetamol through their complexation with cucurbit[7]uril. Org Biomol Chem. 2010;8:765-73 pubmed publisher
    ..beta-blocker drug atenolol, the antidiabetic drug glibenclamide, the Alzheimer's NMDA glutamate receptor drug memantine and the analgesic/antipyretic drug paracetamol by cucurbit[7]uril (CB[7]) has been studied by (1)H nuclear ..
  31. Lockrow J, Boger H, Bimonte Nelson H, Granholm A. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res. 2011;221:610-22 pubmed publisher
    b>Memantine is a partial NMDA receptor antagonist that has been shown to improve learning and memory in several animal models, and is approved for the treatment of Alzheimer's disease (AD)...
  32. Levine T, Bowser R, Hank N, Saperstein D. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotroph Lateral Scler. 2010;11:514-9 pubmed publisher
    The objective of this trial was to determine the safety and tolerability of memantine in patients with sporadic ALS and to examine changes in CSF biomarkers during drug therapy. Twenty patients on stable doses of riluzole were enrolled...
  33. Xia P, Chen H, Zhang D, Lipton S. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30:11246-50 pubmed publisher
    ..b>Memantine, an adamantane derivative, has been used for the treatment of Alzheimer's disease with an excellent clinical ..
  34. Annweiler C, Fantino B, Parot Schinkel E, Thiery S, Gautier J, Beauchet O. Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. Trials. 2011;12:230 pubmed publisher
    ..We hypothesized that the combination of memantine with vitamin D could be neuroprotective in ADRD, thereby limiting neuronal loss and cognitive decline...
  35. Farlow M, Alva G, Meng X, Olin J. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin. 2010;26:263-9 pubmed publisher
    ..the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease receiving concomitant memantine. Post hoc analysis of a 25-week, randomized, prospective, open-label, parallel-group study...
  36. Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian J, Mucke H. Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. J Neural Transm (Vienna). 2011;118:1255-9 pubmed publisher
    b>Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD)...
  37. Quan M, Zhang N, Wang Y, Zhang T, Yang Z. Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience. 2011;182:88-97 pubmed publisher
    ..This study was designed to see whether memantine, a noncompetitive NMDA antagonist, has antidepressant effects in behaviors and synaptic plasticity...
  38. Sani G, Serra G, Kotzalidis G, Romano S, Tamorri S, Manfredi G, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs. 2012;26:663-90 pubmed publisher
    b>Memantine, a non-competitive NMDA receptor antagonist approved for Alzheimer's disease with a good safety profile, is increasingly being studied in a variety of non-dementia psychiatric disorders...
  39. Montagne A, Hébert M, Jullienne A, Lesept F, Le Béhot A, Louessard M, et al. Memantine improves safety of thrombolysis for stroke. Stroke. 2012;43:2774-81 pubmed
    ..b>Memantine, used for treatment of Alzheimer disease, is an antagonist for N-methyl-d-aspartate receptors...
  40. Kotermanski S, Johnson J, Thiels E. Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats. Pharmacol Biochem Behav. 2013;109:67-76 pubmed publisher
    b>Memantine and ketamine block N-methyl-D-aspartate (NMDA) receptors with similar affinity and kinetics, yet their behavioral consequences differ: e.g...
  41. Rueda N, Llorens Martín M, Flórez J, Valdizán E, Banerjee P, Trejo J, et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis. 2010;21:277-90 pubmed publisher
    ..b>Memantine, an uncompetitive NMDA receptor antagonist approved for the treatment of moderate to severe Alzheimer's disease, ..
  42. Forstl H, Stamouli S, Janetzky W, Galanopoulos A, Karageorgiou C, Tzanakaki M. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord. 2011;32:267-72 pubmed publisher
    ..studies, 4,305 patients with mild to severe Alzheimer's disease (AD) were treated with daily doses of 20 mg memantine for 6 months...
  43. Dysken M, Sano M, Asthana S, Vertrees J, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311:33-44 pubmed publisher
    Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD...
  44. Choi S, Park K, Na D, Han H, Kim E, Shim Y, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opin. 2011;27:1375-83 pubmed publisher
    To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer's disease (AD)...
  45. Guadagna S, Bundgaard C, Hovelsø N, Volbracht C, Francis P, Egebjerg J, et al. Memantine potentiates hippocampal ? oscillations at a therapeutic dose in anesthetized mice: a mechanistic link to its cognitive-enhancing properties. Neuropharmacology. 2012;62:2208-18 pubmed publisher
    b>Memantine is an uncompetitive, low-affinity NMDA receptor antagonist clinically used for the treatment of cognitive deficits in moderate to severe Alzheimer's disease...
  46. Costa A. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Dev Neurosci. 2011;33:414-27 pubmed publisher
    ..for DS, with emphasis on our recent results showing that the N-methyl-D-aspartate receptor antagonist memantine can reverse learning and memory deficits in Ts65Dn mice...
  47. Cho G, Lee J, Ju C, Kim C, Kim W. N-Methyl-D-aspartate receptor antagonists memantine and MK-801 attenuate the cerebral infarct accelerated by intracorpus callosum injection of lipopolysaccharides. Neurosci Lett. 2013;538:9-14 pubmed publisher
    ..Intraperitoneal administration of memantine, a NMDA receptor antagonist, reduced the LPS-enhanced calcium response as well as ischemic tissue damage...
  48. Boxer A, Knopman D, Kaufer D, Grossman M, Onyike C, Graf Radford N, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149-56 pubmed publisher
    b>Memantine has been used off-label to treat frontotemporal lobar degeneration (FTD)...
  49. Grant J, Chamberlain S, Odlaug B, Potenza M, Kim S. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl). 2010;212:603-12 pubmed publisher
    Although pathological gambling (PG) is relatively common, pharmacotherapy research for PG is limited. Memantine, an N-methyl D-aspartate receptor antagonist, appears to reduce glutamate excitability and improve impulsive decision making, ..
  50. Doody R, Geldmacher D, Farlow M, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012;33:164-73 pubmed publisher
    ..mg/day versus donepezil 10 mg/day for moderate-to-severe Alzheimer's disease allowed patients taking concomitant memantine. We evaluated the efficacy/safety of donepezil 23 and 10 mg/day in this trial, with respect to concomitant ..
  51. Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother. 2011;12:787-800 pubmed publisher
    ..Understanding the pathogenesis of AD and developing effective treatments is a public health imperative. Memantine is a low- to moderate-affinity, non-competitive NMDA receptor antagonist that is currently approved for the ..
  52. de Bartolomeis A, Sarappa C, Buonaguro E, Marmo F, Eramo A, Tomasetti C, et al. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:1-12 pubmed publisher
    ..Ketamine has also been observed to exacerbate psychotic symptoms in schizophrenia patients. However, memantine, a non-competitive NMDA receptor antagonist approved for Alzheimer's disease and proposed for antipsychotic ..
  53. Ballard C, Corbett A, Chitramohan R, Aarsland D. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr Opin Psychiatry. 2009;22:532-40 pubmed publisher
    ..The purpose of this review is to describe the current state of knowledge regarding management of BPSD, with a particular focus on agitation...